Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Teva Stands By Migraine Strategy After Ajovy Misses Boat On Express Scripts Deal

Oct 18 2018

• By Emily Hayes

Related Content

Schultz Swings The Cleaver At Teva, Cutting 25% Of The Workforce

Dec 14 2017

Best-In-Class Or First-In-Class: CGRP Inhibitors Line Up To Win The Migraine Market

May 09 2017

Amgen's Repatha Contract With Harvard Pilgrim Includes A Full Refund

May 03 2017

Let's Make A Deal: Sanofi/Regeneron Extend A Hand On Praluent, Express Scripts Takes It

May 01 2018

Allergan's Ubrogepant Succeeds In Second Acute Migraine Phase III Study

Apr 28 2018

Is Quarterly Dosing For Teva's Ajovy Enough To Differentiate It From Other CGRP Inhibitors?

Sep 18 2018

Amgen's Aimovig Aims To Capture As Many Migraine Patients As Possible With $6,900 Price

May 18 2018

Allergan’s Oral Drugs Overlooked In CGRP Inhibitor Development Race

Sep 30 2016

Allergan Touts Ubrogepant Phase III Success, But Liver Tox Concerns Overhang

Feb 06 2018

Migraine Drug Atogepant Delivers Good News When Allergan Needs It Most

Jun 11 2018

Related Companies

Teva Pharmaceutical Industries Ltd.

Express Scripts Holding Company

Amgen, Inc.

Novartis AG

Eli Lilly and Company

Sanofi

Regeneron Pharmaceuticals, Inc.

Alder Biopharmaceuticals, Inc.

Allergan plc

Merck & Co., Inc.

Additional Topics

Pricing Strategies Reimbursement Research & Development Neurology BioPharmaceutical

More from Drug Pricing

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window